Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.69
-0.27-5.44%
At close: -
$5.50
0.8117.27%
After Hours: Apr 4, 7:00 AM EDT
Comments
Loading...
Profound Medical Analyst Ratings and Price Targets | NASDAQ:PROF | Benzinga
Profound Medical Corp has a consensus price target of $12.7 based on the ratings of 5 analysts. The high is $18 issued by TD Cowen on May 11, 2023. The low is $10 issued by Jefferies on March 21, 2023. The 3 most-recent analyst ratings were released by Stifel, Alliance Global Partners, and Stifel on July 16, 2024, March 11, 2024, and March 8, 2024, respectively. With an average price target of $10.6 between Stifel, Alliance Global Partners, and Stifel, there's an implied 92.73% upside for Profound Medical Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Alliance Global Partners
TD Cowen
Jefferies
1calculated from analyst ratings
Analyst Ratings for Profound Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 118.18% | Stifel | Rick Wise74% | $9 → $12 | Upgrade | Hold → Buy | Get Alert |
| 03/11/2024 | Buy Now | 96.36% | Alliance Global Partners | Ben Haynor37% | $12.75 → $10.8 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 63.64% | Stifel | Rick Wise74% | $11 → $9 | Maintains | Hold | Get Alert |
| 01/04/2024 | Buy Now | 131.82% | Alliance Global Partners | Ben Haynor37% | $14.25 → $12.75 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 100% | Stifel | Rick Wise74% | → $11 | Initiates | → Hold | Get Alert |
| 08/04/2023 | Buy Now | — | Raymond James | Rahul Sarugaser21% | — | Downgrade | Strong Buy → Outperform | Get Alert |
| 05/11/2023 | Buy Now | 227.27% | TD Cowen | Joshua Jennings53% | $14 → $18 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 186.36% | Alliance Global Partners | Ben Haynor37% | $13.15 → $15.75 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 81.82% | Jefferies | Michael Sarcone10% | $5.5 → $10 | Downgrade | Buy → Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | — | Raymond James | Rahul Sarugaser21% | — | Upgrade | Outperform → Strong Buy | Get Alert |
FAQ
What is the target price for Profound Medical (PROF) stock?
The latest price target for Profound Medical (NASDAQ:PROF) was reported by Stifel on July 16, 2024. The analyst firm set a price target for $12.00 expecting PROF to rise to within 12 months (a possible 118.18% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Profound Medical (PROF)?
The latest analyst rating for Profound Medical (NASDAQ:PROF) was provided by Stifel, and Profound Medical upgraded their buy rating.
When was the last upgrade for Profound Medical (PROF)?
The last upgrade for Profound Medical Corp happened on July 16, 2024 when Stifel raised their price target to $12. Stifel previously had a hold for Profound Medical Corp.
When was the last downgrade for Profound Medical (PROF)?
The last downgrade for Profound Medical Corp happened on August 4, 2023 when Raymond James changed their price target from N/A to N/A for Profound Medical Corp.
When is the next analyst rating going to be posted or updated for Profound Medical (PROF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Profound Medical (PROF) correct?
While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a upgraded with a price target of $9.00 to $12.00. The current price Profound Medical (PROF) is trading at is $5.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.